Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey

•Questions around optimal use of bone-modifying agents (BMAs) still exist.•Most physicians are de-escalating BMAs in patients with metastatic breast cancer.•Practice varies according to patient insurance coverage.•There is interest performing further trials of de-escalation especially after 2 years of treatment.